# Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma

> **NCT04977167** · PHASE1 · UNKNOWN · sponsor: **HitGen Inc.** · enrollment: 96 (estimated)

## Conditions studied

- Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** HG146
- **DRUG:** PD-(L)1 antibody

## Key facts

- **NCT ID:** NCT04977167
- **Lead sponsor:** HitGen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-28
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2024-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04977167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04977167, "Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04977167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*